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Summary. The American College of Cardiology (ACC)and the American Heart Association (AHA) have pro-
vided leadership in enhancing the quality of cardiovascular
care, including the development of clinical performance
measures and clinical registries that permit the evaluation of
quality of care and stimulate quality improvement. Compli-
ance with ACC/AHA performance measures and metrics
encourages the provision of the strongest evidence-based
quality of care, including therapies that are life-extending or
life-enhancing. Among quality metrics, only a subset should
be considered performance measures—that is, those measures
specifically suitable for public reporting, external compari-
sons, and possibly pay-for-performance programs, in addition
to quality improvement. These performance measures have
been developed using ACC/AHA methodology, often in
collaboration with other organizations, and include the pro-
cess of public comment and peer review. Quality metrics are
those measures that have been developed to support self
assessment and quality improvement at the provider, hospital,
and/or health care system level. These metrics represent
valuable tools to aid clinicians and hospitals in improving
quality of care and enhancing patient outcomes, but may not
meet all specifications of formal performance measures.
These quality metrics may also be considered “candidate”
measures that with further research of field testing would
meet the criteria for formal performance measures in the
future. This measure classification is intended to aid provid-
ers, hospitals, health systems, and payers in identifying those
measures that the ACC and AHA formally endorse as
performance measures, while at the same time promoting the
broader range of clinical metrics that are useful for quality
improvement efforts.
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Recognition that the quality of health care in the United
States is suboptimal has provoked substantial interest in the
development of metrics to assess care quality and to serve as
outcome targets for quality improvement initiatives. The
ACC and the AHA have provided national leadership in
improving the quality of cardiovascular care, including the
development of performance measures as well as clinical
registries that permit the evaluation of quality metrics. Im-
portantly, not all care metrics carry the same level of strength
and rigor. The term performance measures will be reserved
for selected cardiovascular quality metrics with attributes
rendering them suitable for public reporting and for explicit
comparisons of care between institutions and/or healthcare
providers. This document provides a classification scheme to
differentiate care metrics that meet the criteria for perfor-
mance measures and have been selected by the ACC/AHA
Task Force on Performance Measures from those that are
intended to support quality improvement but do not meet all
the necessary attributes and/or were not selected as ACC/
AHA performance measures. For the purposes of clarity in
this document, measures not meeting the criteria of perfor-
mance measures are referred to as quality metrics, although in
practice, other terms may be used (eg, quality measures,
quality improvement measures, or test measures).
Quality metrics, including performance measures, often
focus on processes of care for which recommendations in
practice guidelines are of adequate strength that the failure to
follow the recommendations is likely to result in suboptimal
patient outcomes (eg, warfarin for patients with nonvalvular
atrial fibrillation, beta blockade after myocardial infarction,
angiotensin-converting enzyme inhibitors or angiotensin re-
ceptor antagonists for heart failure with left ventricular
systolic dysfunction). Compliance with ACC/AHA perfor-
mance measures and metrics encourages the provision of the
strongest evidence-based quality of care, including therapies
that are life-extending or life-enhancing. However, quality
metrics may also extend beyond processes of care, reflecting
structures of care (eg, procedural volume or staffing ratios),
efficiency in care delivery (eg, readmission rates after heart
failure hospitalization), or patient outcomes (eg, mortality
after myocardial infarction).
Among quality metrics, only a subset should be considered
performance measures—that is, specifically intended for public
reporting, external comparisons, and possibly pay-for-
performance programs. The ACC/AHA Task Force on Perfor-
mance Measures has thus far developed 4 sets of performance
measures comprising key processes and/or structural measures
of care for heart failure, acute myocardial infarction, cardiac
rehabilitation, and atrial fibrillation (1–4). In addition, perfor-
mance measures for peripheral arterial disease and primary
prevention of cardiovascular disease are in development. Mea-
sures for stroke care have been separately developed under the
oversight of the AHA in collaboration with the American Stroke
Association and other organizations. Each of the writing groups
from which performance measures have emanated has carefully
adhered to the rigorous ACC/AHA methodology of performance
measure development (5). The measure development process
includes the selection of candidate measures by the writing
groups, the evaluation of the extent to which these candidates
meet the desired attributes of performance measures, and sub-
sequent public comment, peer review, final review by ACC/
AHA Task Force on Performance Measures, and approval by
the ACC and AHA. In some cases, the task force may also
review metrics developed by external organizations and may
endorse these metrics as performance measures based on the
extent to which they meet the measures attributes endorsed by
the ACC/AHA.
Although an important focus of the Task Force on Perfor-
mance Measures and the individual writing groups is the
development of metrics that are useful to support quality
improvement efforts, it is understood that those metrics
designated as performance measures may also be used by
other organizations for external review or public reporting of
performance. Hence it is within the purview of the task force
and writing groups to identify the strengths and limitations of
each metric and the appropriateness of using metrics for the
purposes of public accountability. In some cases, candidate
metrics may be deemed as test measures or quality improve-
ment measures that are not felt to be suitable for public
reporting because they do not meet the standards of perfor-
mance measures for public reporting (5), yet may still have
critical value for informing local quality improvement and/or
may evolve into performance measures (5).
The ACC/AHA Task Force has worked directly with the
Physicians Consortium for Performance Improvement (PCPI)
of the American Medical Association, the Center for Medi-
care and Medicaid Services (CMS), the Joint Commission,
the National Quality Forum (NQF), and other organizations
in identifying those measures that may be suitable for public
reporting. The measures developed thus far by the ACC/AHA
Task Force have been derived using rigorous methodology
and have undergone such extensive peer review and periods
of public comment that the ACC and the AHA approve these
measures for purposes of public reporting.
At the same time, the ACC and AHA are extensively
involved in many other facets of quality improvement,
including quality alliances, quality education, and quality
improvement registries/programs such as the National Car-
diovascular Data Registry (NCDR) (6) and Get With the
Guidelines (GWTG) programs (7,8). These initiatives often
measure aspects of care and patient outcomes that are
intended to assist physicians and hospitals in measuring and
improving their care. The GWTG programs have since
inception used the terms GWTG performance measures,
quality measures, and reporting measures for metrics used by
the program and to distinguish the measures used to select
hospitals for program recognition. The metrics of these
initiatives may include, but are not limited to, the perfor-
mance measures developed using the rigorous ACC/AHA
performance measurement methodology and selected in the
measures development process described above.
It is important to emphasize that the ACC and AHA strongly
believe in the value of quality metrics that are not designated
performance measures as a means of stimulating important
improvements in care and outcomes at the physician, hospital,
and healthcare system level. Moreover, the ACC/AHA Task
Force on Performance Measures may ultimately select such
quality metrics as performance measures after adequate evalua-
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tion. However, such quality metrics may not currently meet all
of the standards necessary to deem them performance measures.
To date, there has not been a clear designation of which
metrics that arise from various quality initiatives of the ACC
and AHA represent performance measures versus quality
improvement metrics. The ACC and AHA thereby strongly
recommend that only metrics for cardiovascular disease that
have been developed formally using the published ACC/
AHA performance measure methodology (5,9) and measures
development process be designated as ACC/AHA perfor-
mance measures. The ACC/AHA may also identify selected
metrics developed by external organizations for endorsement
as performance measures.
To distinguish between cardiovascular performance
measures and other quality metrics, the ACC/AHA Task
Force on Performance Measures has adopted the following
classification:
Performance Measures are those process, structure,
efficiency, or outcome measures that have been devel-
oped using ACC/AHA methodology, including the pro-
cess of public comment and peer review (5,9), and have
been specifically designated as performance measures
by the ACC/AHA Task Force on Performance Mea-
sures. This may occur in collaboration with PCPI, CMS,
the Joint Commission, and/or NQF. These measures are
intended not only for clinical quality improvement but
also may be considered for purposes of public reporting
or other forms of accountability.
Quality Metrics are those measures that have been
developed to support self-assessment and quality
improvement at the provider, hospital, and/or health-
care system level. These metrics may not have been
formally developed using the ACC/AHA perfor-
mance measure methodology, though they may be
identified as “preliminary,” “candidate,” “test,”
“evolving,” or “quality” measures that may be worthy
of consideration for further development into perfor-
mance measures. In the course of their work, writing
groups may identify measures that do not meet the
strict criteria for performance measures and identify
such measures as “quality metrics.” However, these
metrics may also be developed by other components
of the ACC or AHA to support quality initiatives,
such as NCDR or GWTG. These metrics thereby
represent valuable tools to aid clinicians and hospitals
in improving quality of care and enhancing patient
outcomes but may not meet all specifications of
formal performance measures. These quality metrics
may also be considered “candidate” measures that, with
further research or field testing, would meet the criteria
for formal performance measures in the future.
This measure classification is intended to aid providers,
hospitals, health systems, and payers in identifying those
measures that the ACC and AHA formally endorse as
performance measures, while at the same time promoting the
broader range of clinical metrics that are useful for quality
improvement efforts. This classification has undergone peer
review and approval by content reviewers of the ACC and
AHA and by leadership of NCDR and GWTG and has been
approved by the Board of Trustees of the ACCF and the
Science Advisory and Coordinating Committee of the AHA.
The ACC/AHA Task Force on Performance Measures will
work closely with other ACC and AHA quality initiatives as
well as external bodies to carefully examine and evaluate
measures individually with regard to their designation as
performance measures or quality metrics.
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